{"id":77985,"date":"2022-06-09T00:00:00","date_gmt":"2022-06-09T05:00:00","guid":{"rendered":"https:\/\/www.unmc.edu\/newsroom\/2022\/06\/09\/unmc-sees-continued-success-in-ultra-long-acting-hiv-medicines-2\/"},"modified":"2024-03-27T12:13:53","modified_gmt":"2024-03-27T17:13:53","slug":"unmc-sees-continued-success-in-ultra-long-acting-hiv-medicines-2","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/newsroom\/2022\/06\/09\/unmc-sees-continued-success-in-ultra-long-acting-hiv-medicines-2\/","title":{"rendered":"UNMC sees continued success in ultra-long acting HIV medicines"},"content":{"rendered":"

UNMC has long been at the forefront of research and development of ultra-long acting antiviral therapy (ART) designed as vaccine mimetics for pre-exposure prophylaxis (medicine taken to prevent HIV), extended viral suppression and to facilitate in the elimination of HIV-1 infection. Now, the UNMC scientific team has extended their know-how by developing libraries of ultra-long acting medicines.   <\/p>\n

This effort has taken a major step forward with the publication of new data today. The data shows that a daily, effective oral treatment used by patients living with HIV worldwide can be, in animal models, transformed into a single, annual injectable.<\/p>\n

Clinical trials may start as early as 2023, researchers said.<\/p>\n


\n
\n
\n

\n\"picture
\n<\/TD>
\n
\n\"picture
\n<\/TD>
\n<\/TR>
\n

\n
\nBrady Sillman, PhD
\n<\/FONT>
\n<\/TD>
\n
\n
\nSuyash Deodhar
\n<\/FONT>
\n<\/TD>
\n<\/TR>
\n<\/TABLE><\/p>\n

Physiochemical and pharmacokinetic (PK) formulation properties of an integrase strand transfer inhibitor (INSTI) prodrug nanocrystal facilitates slow drug release. The identified macrophage storage “depot” at the muscle injection site permits drug dissemination through the body at sites where the virus replicates throughout the year.<\/p>\n

These research findings for the INSTI prodrug were published today in Nature Communications in an article titled “Transformation of dolutegravir from daily oral to ultra-long-acting parenteral injectable.”<\/a><\/p>\n

“It is the ultra-long extended duration of action of this new investigative UNMC prodrug (XVIR-120) that is the game-changer,” said Benson Edagwa, PhD, associate professor in the UNMC Department of Pharmacology and Experimental Neuroscience (PEN), who designed the prodrugs and formulations. “Currently, daily regimen adherence to oral antivirals effectively suppresses and prevents HIV — if you don’t forget to take your pills.”<\/p>\n

But anyone who has had to stick to even a temporary 10-day prescription knows how easy it is to miss a day.<\/p>\n

\n

The UNMC team<\/h3>\n